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Summary In this study, we have investigated the expression of the proto-oncogene c-erbB2 in a total of 70
human primary breast tumours. In agreement with other workers, we observed c-erbB2 gene amplification in
17.5% of the tumours studied. In addition, we carried out a comprehensive analysis of c-erbB2 mRNA
expression in the tumours using RNase mapping and in situ hybridisation techniques. Our results indicated a
more frequent (30%) overexpression of c-erbB2 mRNA, which was associated only with breast carcinomas of
a ductal origin. Furthermore, analysis of the c-erbB2 mRNA gene locus in the same tumours demonstrated
that enhanced c-erbB2 expression could occur in the presence or absence of gene amplification, suggesting that
additional molecular mechanisms may result in overexpression of c-erbB2 mRNA in human mammary
tumours. In situ hybridisation showed that elevated levels of c-erbB2 mRNA were specific to malignant cells
within the breast tumour. Analysis of the association between c-erbB2 mRNA overexpression and clinico-
pathological factors revealed a significant correlation with poor tumour grade, but not with steroid receptor
status or patient menopausal status. No significant correlation was observed between overexpression of
c-erbB2 mRNA and early disease recurrence in our group of patients, although there was a definite trend
towards poorer prognosis.
Recent efforts in cancer research have been directed at
finding molecular markers of potential predictive value in
tumour prognosis. There is increasing evidence to link the
activation of cellular proto-oncogenes with the initiation or
progression of particular human malignancies. In human
breast carcinoma, several such genes have been found to be
amplified or rearranged, including c-myc and c-ras (Whit-
taker et al., 1986; Escot et al., 1986), although the role of
these proto-oncogenes in the progression of the disease is, as
yet, unclear.
There is at present much controversy surrounding the
potential role of the human proto-oncogene c-erbB2 (also
known as neu or HER2) in breast cancer prognosis (Ali et
al., 1988a; Slamon & Clark, 1988). C-erbB2 is related to, but
distinct from, the c-erbBl/EGF receptor gene (Bargmann et
al., 1986; Yamamoto et al., 1986) and maps to band q21 on
chromosone 17 (Fukushige et al., 1986; Coussens et al.,
1985). It encodes a normal cellular glycoprotein showing
structural features of a growth factor receptor, including a
transmembrane region and a tyrosine kinase domain
(Akiyama et al., 1986), although its ligand has not yet been
identified. Many tissues express c-erbB2 transcripts. However,
observations that amplifications of the c-erbB2 gene is limited
to carcinomas of glandular epithelial origin (Yokota et al.,
1986) have led to the suggestion that the c-erbB2 gene
encodes a growth factor receptor associated with glandular
epithelium (Zhou et al., 1987).
The c-erbB2 gene is amplified relatively frequently in
human primary breast carcinomas, although the frequency
and level of amplification observed in different studies varies
widely, in the range 10-40% (Slamon et al., 1987; Van de
Vijver et al., 1987; Venter et al., 1987; Ali et al., 1988b;
Berger et al., 1988). Clinical interest in the c-erbB2 gene with
respect to breast cancer prognosis has been stimulated by the
reports of Slamon et al. (1987) and Varley et al. (1987) that
amplification of the c-erbB2 gene is a significant predictor of
decreased survival time and rapid relapse in patients. Slamon
et al. (1987) reported that c-erbB2 amplification had greater
prognostic significance than most currently used indicators in
lymph node-positive disease. However, recent primary breast
tumour DNA studies by other groups (Zhou et al., 1987,
1989; Ali et al., 1988a,b) have failed to confirm the prognos-
tic significance of this finding. Immunocytochemical inves-
tigations on the c-erbB2 protein in breast carcinomas by
some groups have not established a positive correlation
between the expression of c-erbB2 and tumour recurrence
(Barnes et al., 1988; Van de Vijver et al., 1988). However,
Wright et al. (1989) have reported that expression of the
oncoprotein is an important prognostic indicator.
We have investigated the amplification of the c-erbB2 gene
in a series of clinically well-defined primary breast tumours,
and have examined the levels of expression of c-erbB2
mRNA within these tumours by RNase mapping. The
degrees of c-erbB2 DNA amplification and mRNA over-
expression in the tumours have been correlated with clinical
parameters of prognosis in order to evaluate whether they
are significant predictors of relapse or survival time in breast
cancer. Furthermore, since the conflicting results between
different tumour studies may be attributed to heterogeneity
of the tumour cell population, we have investigated the dis-
tribution of c-erbB2 mRNA within the breast tumour tissue
by in situ hybridisation. This allows an assessment of the
levels of c-erbB2 mRNA in individual normal and malignant
cells within the tumour.
Materials and methods
Patients andpathological material
Material for this study was obtained from 70 patients
presenting with primary breast carcinomas at the Christie
Hospital and Holt Radium Institute, Manchester, between
1984 and 1986. The majority of these patients (95%) were
treated, either by simple mastectomy (52%) or by excision
biopsy (43%). The age range of the patients was 33-88, with
a median of 60. Tumours excised from these patients
included 60 infiltrating ductal carcinomas, seven infiltrating
lobular carcinomas, one of mixed type, one invasive duct
carcinoma with a predominant intraductal component and
one of unknown pathology. Clinical follow-up data, to the
time of this study, were available for all of the patients. Of
the 70 cases, 54% received no postoperative therapy, 39%
received radiotherapy and 7% had adjuvant tamoxifen treat-
ment. Reduction mammoplasty tissue was used as a source of
normal breast tissue.
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Tumour samples for RNA/DNA extraction were frozen in
liquid nitrogen immediately after excision. For in situ hy-
bridisation studies, formalin fixed tissue from the same
primary breast tumours was processed and embedded in
paraffin wax in routine pathology laboratories, without
special precautions to prevent RNA degradation. It was then
stored at ambient temperatures.
RNA and DNA extraction
Tumour tissues DNA and RNA were extracted from the
same tumour sample after centrifugation of the homogenised
tumour tissue through a CsCl cushion. Total RNA was
isolated as described by Parkes et al. (1988). The DNA was
isolated by removing the interface between the CsCl cushion
and the supernatant. This fraction was then diluted to 10 ml
with 10mM Tris-HC1 (pH 7.5)/10 mM EDTA, and extracted
twice with phenol/chloroform/iso amyl alcohol (24:24:1 by
volume) and twice with chloroform before ethanol precipita-
tion. Sufficient DNA for further analysis was obtained from
59 out of the 70 tumours, while 62 of the tumour samples
yielded RNA of suitable quality for RNase mapping
experiments.
DNA was extracted from the peripheral blood lym-
phocytes of breast tumour patients by the method of Jean-
pierre (1987).
Probes
C-erbB2 The plasmid pSV2-erbB2, which contains a full
length c-erbB2 cDNA clone in the vector pSV2 (Yamamoto
et al., 1986) was digested to completion with either Kpn
I/Hind III or Taq I/Hind III to release 1234 bp and 656 bp
fragments, respectively, from the 3' region of the c-erbB2
gene. These fragments, which have only limited homology to
the c-erbB1/EGF receptor gene, were subcloned into pGem 4
Blue and pGem 3 Blue respectively.
For Southern blot analysis of c-erbB2 the Kpn I/Hind III
fragment was excised from the pGem4 Blue construct and
radiolabelled with a-32P dCTP (3,000 Ci mmol-') by the ran-
dom primer method of Feinberg and Vogelstein (1984).
For RNase mapping and in situ hybridisation studies,
c-erbB2 RNA probes were made from the pGem 3 Blue/
c-erbB2 construct, containing the Taq I/Hind III c-erbB2
fragment. The plasmid was linearised with either Hind III or
Eco RI and transcribed with T7 or Sp6 RNA polymerase,
respectively, to produce sense (mRNA) or anti-sense (cRNA)
transcripts.
Human growth hormone (hGH) An 816 bp Pst I cDNA clone
(L. Hall, unpublished).
Gastrin A 549 bp Pst I cDNA clone (Boel et al., 1983).
D5S6 A human genomic clone containing a 7.6 kb insert
representing asinglecopy sequence fromchromosome 5, cloned
in the bacteriophage vector L47 1. D5S6 identifies three allelic
RFLPs upon hybridisation to Bam HI digested genomic DNA
(Dietzch et al., 1986).
DNA analysis
Five micrograms of DNA were digested with Eco RI or Bam
HI and electrophoresed through a 0.8% agarose gel. The
DNA was blotted on to Hybond-N membrane (Amersham
International plc; Amersham, UK) and cross-linked to the
membrane by UV-illumination as described by the manufac-
turer. The membrane was hybridised at 65°C overnight with
106 c.p.m. ml1' of radiolabelled probe in 6 x SSC, 5 x Den-
hardt's solution, 0.5% SDS and 500gigml-' of denatured
sonicated salmon sperm DNA. The blot was then washed to
high stringency (0.5 x SSC at 65°C) and autoradiographed
for 1-3 days at -70°C using Kodak X-Omat XAR5 film.
Blots were stripped of probe by submerging in boiling water
for 5 min and were pre-hybridised and re-hybridised, using a
second labelled probe, as before.
Preparation ofRNA probes
RNA probes radiolabelled with a-32P CTP (800 Cimmol ')
were synthesised as follows. The pGem Blue 3/c-erbB2 con-
struct was linearised with Eco RI and transcribed with Sp6
RNA polymerase (Promega) according to the manufacturer's
instructions. DNase I (BCL) was added to digest the DNA
template. The radiolabelled transcripts were then purified by
electrophoresis on a 6% polyacrylamide-urea gel (Smith et
al., 1988). Labelled RNA species of the correct size were
identified by brief autoradiography, eluted from the gel by
shaking overnight in 0.5M ammonium acetate, 10mM mag-
nesium acetate, 1mM EDTA and 0.1% SDS and were then
ethanol precipitated with 10gig of carrier tRNA.
RNaseprotection analyses
Approximately 1 x I05 c.p.m. of purified RNA probe were co-
precipitated with 5gig of tumour total RNA and resuspended in
30gi of hybridisation buffer (80% formamide, 50mM PIPES
pH 6.7, 400 mM NaCI, 1 mM EDTA) as described by Zinn et
al. (1983). After heating to 85°C for 20min, the samples were
incubated at 56°C overnight. Three hundred microlitres of
RNase digestion buffer (0.3 M NaCl, 10 mM Tris-HC1 pH 7.5,
5 mM EDTA, 20OLg mlP
I RNase A, IiLg ml- I RNase TI) was
added to each tube and samples were incubated for 30min at
30°C. The RNase-resistant duplexes were deproteinised by addi-
tion of 20gil of 10% SDS and 50 igml-' proteinase K, fol-
lowed by incubation at 37°C for 15min, and extraction with
phenol/choloroform/isoamyl alcohol (24:24:1 by volume). Resid-
ual RNA fragments were then concentrated by ethanol precipi-
tation in the presence of 5 gig tRNA, washed in 70% ethanol
and resolved by electrophoresis under denaturing conditions on
a 6% polyacrylamide-urea gel.
In situ hybridisation
This was carried out essentially as described by Parkes
et al. (1988), with the following modifications. The c-erbB2
RNA transcripts were radiolabelled with a-3 S CTP
(1,350 Ci mmol-'). The hybridisation was then performed in
the presence of 10mM DTT and the subsequent washes in
the presence of 5 mM DTT.
Results
C-erbB2 gene amplification in primary breast tumours
DNA isolated from 57 primary breast tumours was analysed
with a c-erbB2 cDNA probe. Amplification of the human
c-erbB2 gene was observed in 10 cases (17.5%), all of which
were infiltrating ductal carcinomas. The degree of
amplification was estimated both by performing serial dilu-
tions of the DNA samples and by laser scanning densit-
ometry.
Figures 1 and 2b show the results obtained from Southern
blotting analysis of 16 of the tumour DNA samples.
Moderate amplification (2-3-fold) of the 10 kb c-erbB2 frag-
ment was seen in tumours 95 and 78, while a higher level of
amplification was observed in tumours 40, 64 and 80. The
latter tumour had, in addition, a smaller fragment of 5.6 kb
which was highly amplified. Preliminary studies have
indicated that this represents rearrangement of the c-erbB2
gene, a rare event only observed in this single case out of the
57 tumours analysed. Examples of DNA which did not con-
tain amplified c-erbB2 gene copies are also shown (Figures 1
and 2b; tumours 21, 42, 70, 69, 117, 106, 59, 94, 112).
Normal human lymphocyte DNA was analysed in parallel on
each gel as a control for levels of single copy c-erbB2.
In order to control for slight differences in loading of
tumour DNA and for DNA degradation, all filters were
stripped of the c-erbB2 probe and rehybridised with D5S6, a
single copy genomic DNA probe from chromosome 5. D5S6
hybridises to DNA fragments of 11 kb, 9 kb and 7.5 kb andC-erbB2 EXPRESSION IN BREAST TUMOURS 41
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Figure 1 Southern blot analysis comparing the gene copy number of c-erbB2 in breast tumour DNA and in lymphocyte DNA
from the same patient. Tumour (T)/lymphocyte (L) DNA pairs were digested with Bam HI and hybridised to a 32P-labelled c-erbB2
cDNA probe. Lane C shows lymphocyte DNA from a healthy individual. The size markers used (lane M) were a Hind III digest of
DNA.
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Figure 2 The analysis of c-erbB2 mRNA overexpression and DNA amplification in human primary breast carcinomas. a, RNase
mapping of c-erbB2 RNA in a series of breast tumours. RNase-protected fragments of c-erbB2 mRNA (656 bp) are shown. A
negative control containing E.coli tRNA was also analysed (lane R). Lane P shows undigested hybridisation probe. b, Southern
blotting analysis of c-erbB2 DNA in a series of breast tumours. Tumour DNA was digested with Bam HI, blotted and hybridised
with a 32P-radiolabelled c-erbB2 cDNA probe. c, Rehybridisation of the DNA blot (b) with a 32P-radiolabelled gastrin cDNA
probe.
therefore provides a suitable marker for the amount of high
molecular weight DNA present in each track. The relative
intensity of this signal in each tumour track was used to
normalise the autoradiographic signals obtained with the
other probes (data not shown).
To assess whether the apparent levels of c-erbB2
amplification were due to genuine amplification or due to an
increase in the copy number of chromosome 17, on which the
c-erbB2 gene lies (17q21-q22), the Southern blot filters were
rehybridised with two probes from chromosome 17. These
were a gastrin cDNA probe (localised to 17q) (Lund et al.,
1986) (Figure 2c) and a human growth hormone cDNA
probe (17q22-q24) (Barsh et al., 1983; data not shown).
These genes were present at single copy numbers in all cases,
demonstrating that the c-erbB2 gene amplification observed
was real and not due to an increase in the ploidy of
chromosome 17.
Lymphocyte DNA was available for several of the patients
whose tumours exhibited amplification of the c-erbB2 gene.
Southern blot analysis of these tumour-lymphocyte pairs
(Figure 1) showed that the amplifications (tumours 40, 64,
95) and the one rearrangement (tumour 80) observed were
present only in the tumour DNA of that patient and not in
the lymphocyte DNA, suggesting that these amplifications
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and rearrangement arose specifically in the breast tumour
and were not a result of germline transmission.
Overexpression ofc-erbB2 RNA in primary breast tumours
Sixty-two human primary breast tumours were analysed for
c-erbB2 mRNA expression by RNase mapping, using 32P-
labelled RNA probes derived from the 3' non-coding region
of the c-erbB2 gene. C-erbB2 transcripts were found to be
overexpressed in 19 of the 62 tumour RNA samples mapped
(30%) at levels ranging from 2 to 10-fold (Figure 2a), relative
to a sample of 'normal' breast RNA, quantitated by den-
sitometry. In order to visualise weaker bands in tumour
samples expressing low levels of c-erbB2 RNA, the
autoradiograms were exposed for long periods. The bands in
tumour samples which overexpress c-erbB2 RNA are there-
fore overexposed. The integrity of the RNA used had been
confirmed in a previous study (Parkes et al., 1988).
Of the 70 tumours from which RNA and/or DNA were
isolated, there were 49 samples suitable for examination of
both c-erbB2 DNA amplification and c-erbB2 RNA expres-
sion. In every case in which the c-erbB2 gene copy number
was increased there was concomitant overexpression of c-
erbB2 RNA (Figure 2b and lb respectively). The increase in
levels of c-erbB2 RNA was approximately proportional to
the degree of amplification of the gene. However, in several
cases (8/16) we observed overexpression of c-erbB2 RNA
with no detectable accompanying amplification of the c-
erbB2 gene (Figure 2a, tumour 94). This suggests that there
must be an additional mechanism(s), other than gene
amplification, that can lead to deregulation of c-erbB2
mRNA expression. The RNase mapping experiments did not
show any evidence of anomalies in the 3' ends of the breast
tumour RNAs under investigation.
Localisation ofc-erbB2 RNA within breast tumours by in situ
hybridisation
We employed in situ hybridisation (ISH) using 35S-labelled
c-erbB2 cRNA probes to identify cells synthesising c-erbB2
RNA in paraffin-embedded, formalin-fixed breast tumour
sections. The c-erbB2 cRNA localised specifically to tumour
cells within the breast tissue sections (Figure 3a,b,c). There
was no significant hybridisation observed over normal breast
tissue within the same sections (Figure 3a), or in control
sections processed in parallel but probed with 35S-labelled
c-erbB2 mRNA probes (Figure 3d).
We also investigated the possibility that the failure to
detect c-erbB2 RNA overexpression in some tumour samples
could be due to heterogeneity within the tumour cell popula-
tion, allowing tumour cells with increased levels of c-erbB2
RNA to be 'overshadowed' by larger numbers of normal
breast cells. As ISH detects expression of c-erbB2 RNA
within individual cells, we could determine whether the
tumour cells within a tissue section overexpressed c-erbB2
RNA even when overexpression of c-erbB2 RNA had not
been detected using RNase mapping. We therefore carried
out ISH with a 35S-labelled c-erbB2 cRNA probe on sections
from six tumours, for which we had previously determined
c-erbB2 RNA levels. Two tumours in which we detected no
increase in c-erbB2 levels showed no intense hybridisation to
tumour cells within the section (Figure 4a). As expected,
sections from the four tumours in which we had previously
shown elevated levels of c-erbB2 showed strong hybridisation
(Figure 4b). Again, parallel controls probed with a 35S-
labelled cRNA probe showed no significant hybridisation.
Correlation between c-erbB2 DNA amplification and RNA
overexpression and clinicopathologicalfeatures
We used the x2 test for rectangular contingency tables to
examine the association between increased levels of c-erbB2
and a variety of clinical parameters, in order to evaluate the
potential role of c-erbB2 as a prognostic indicator in the
pathogenesis of breast cancer (Tables I, II and III).
When the correlation between c-erbB2 DNA amplification
and disease recurrence was examined (Table I) a trend
towards an association was noted, which approached
significance. Slamon et al. (1987) reported that the correla-
tion between c-erbB2 gene amplification and poor prognosis
was more convincing for tumours with at least 5-fold gene
amplification. Therefore, we analysed this relationship in our
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Figure 3 Identification of c-erbB2 mRNA by in situ hybridisation. Sense (mRNA) and antisense (cRNA) c-erbB2 transcripts were
used for in situ hybridisation to formalin fixed, paraffin embedded breast tumour sections. a, c-erbB2 cRNA probe ( x 10); b,
c-erbB2 cRNA probe ( x 20); c, c-erbB2 cRNA probe ( x 40); d, c-erbB2 mRNA probe ( x 20).C-erbB2 EXPRESSION IN BREAST TUMOURS 43
TableIII Correlation betweenincreasedc-erbB2 RNAexpressionand
clinico-pathological features. IDC, infiltrating ductal carcinoma; ILC,
infiltrating lobular carcinoma.
Levels ofc-erbB2 RNA
Status n Normal Increased
Tumour pathology 60 42 18
IDC 53 35 18 P>0.05
ILC 7 7 0 <0.1
Tumourgrade (IDC) 53 35 18
I 3 3 0 P=0.05
II 29 21 8
III 21 11 10
Menopausal status 62 43 19
pre 20 14 6 n.s.
peri 3 1 2
post 39 28 1 1
Oestrogen receptor (ER) 62 43 19
positive (+) 34 22 12 n.s.
negative(-) 28 21 7
Progesterone receptor (PR) 62 43 19
positive (+) 28 22 6 n.s.
negative(-) 34 21 13
Combined receptors 62 43 19
ER+/PR+ 20 15 5
ER+/PR- 14 7 7 n.s.
ER-/PR+ 8 7 1
ER-/PR- 20 14 6
&~~~~~~~~~ om;-M.
Figure 4 Identification of c-erbB2 mRNA by in situ hybridisa-
tion using a 35S-labelled c-erbB2 cRNA probe. a, tumour (PB60)
with no detectable increase in c-erbB2 levels; b, tumour (pB127)
with increased c-erbB2 levels.
study (Table II). However, we did not observe an association
of any greater significance between higher levels of c-erbB2
gene amplification and disease recurrence or overall survival
time.
In view of the fact that elevated c-erbB2 expression can
occur in the absence of gene amplification, we have examined
in greater detail the potential prognostic significance of
Table I Association between levels ofc-erbB2 and disease status
Levels ofc-erbB2
Disease status n Normal Increased
RNA expression 62/59* 43/41* 19/16*
survivors 58/55* 43/41* 15/12* P>0.001/<0.001*
deceased 4 0 4 <0.005
relapsed 29 18 1 1 P = 0.25/>0.05
disease-free 33/30* 25/23* 8/5* <0.1*
DNA amplification 57/54* 47/44* 10
survivors 51/48* 44/41* 7 P> 0.025
deceased 6 3 3 <0.05
relapsed 25 18 7 P>0.05
disease-free 32/29* 29/26* 3 <0.1
*Excluding patients who received adjuvant tamoxifen treatment.
Table II Association between elevation of c-erbB2 and disease
status
Elevation ofc-erbB2
Disease status n* 0 2-4fold S-JOfold
RNA expression 57 41 8 8
survivors 53 41 6 6 P>0.005
deceased 4 0 2 2 <0.01
relapsed 29 18 6 5 P>0.2
disease-free 28 23 2 3 <0.25
DNA amplification 54 44 4 6
survivors 48 41 4 3 P>0.005
deceased 6 3 0 3 <0.01
relapsed 25 18 2 5 P>0.1
disease-free 29 26 2 1 <0.2
c-erbB2 RNA overexpression in breast tumours. A significant
correlation was observed between c-erbB2 RNA expression
and tumour grade (P = 0.05); poorly differentiated grade III
tumours having higher levels of c-erbB2 RNA than grade I
or II tumours (Table III). There was, however, no significant
correlation found between c-erbB2 RNA expression and
other clinical features such as patient age or menopausal
status and oestrogen and progesterone receptor status. No
elevation of c-erbB2 RNA levels was observed in any of the
infiltrating lobular carcinomas examined in this study (Table
III), although this group of tumour type was small (7/62).
Fifty-eight per cent of patients with increased c-erbB2
RNA expression had suffered a relapse, as compared with
42% for the population with 'normal' c-erbB2 RNA levels.
When the disease-free interval was plotted against the percen-
tage of patients with a recurrence, for both the normal and
the elevated c-erbB2 RNA populations (Figure 5), a slight
trend was noted. However, this trend did not seem to be
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Figure 5 Disease-free interval after removal of primary breast
tumour. 0, normal c-erbB2 levels; *, increased c-erbB2 levels.
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associated specifically with short term relapse as has been
observed by Varley et al. (1987) for c-erbB2 DNA
amplification. The most significant correlation observed was
between overexpressed c-erbB2 RNA and decreased overall
survival time (P = 0.001) (Table I). However, this association
was determined on a very small sample number (six patients)
and should therefore be confirmed using a larger series of
breast tumours. Again, no more significant an association
was observed between tumours with the highest elevation of
c-erbB2 RNA levels and disease recurrence or survival (Table
II).
As patients' prognoses may to some extent be dependent
upon postoperative therapy, we took into account the
adjuvant therapy received by patients when assessing the
association between c-erbB2 expression and prognosis. Only
five patients (7%) received adjuvant therapy. However, it is
interesting to note that none of these cases had relapsed,
although three had tumours with elevated c-erbB2 RNA
levels. When these tamoxifen-treated patients were excluded
from the disease recurrence study (Table I), the trend
towards an association between c-erbB2 levels and relapse
approached significance (P = 0.05-0.1).
Discussion
In this study we have undertaken a comprehensive survey of
both c-erbB2 gene amplification and mRNA overexpression
within the same human primary breast tumours. We
observed frequent increases in c-erbB2 gene copy number
(17.5%). This result is in general agreement with the c-erbB2
gene amplification frequency observed by most other groups
(Van de Vijver et al., 1987; Varley et al., 1987; Berger et al.,
1988), but lower than the figure of 40% given by Slamon et
al. (1987) for his group of node positive patients. We also
observed a rare rearrangement of the c-erbB2 gene in one of
the tumours studied (1.7%). Slamon et al. (1987) noted a
rearrangement in 1.6% of tumours studied.
DiFiore et al. (1987) have demonstrated that the level of
the c-erbB2 gene product is critical in determining its trans-
forming ability in NIH 3T3 cells. Therefore quantitation of
levels of c-erbB2 RNA expression in human breast car-
cinomas is of interest. In our comprehensive study we have
investigated the level of c-erbB2 mRNA overexpression in 68
tumours by RNase mapping.
A significant difference was observed in the frequency of
c-erbB2 mRNA overexpression (30%) compared with
c-erbB2 gene amplification (17.5%) in the same tumour
group. Although c-erbB2 gene copy amplification was always
accompanied by an equivalent increase in c-erbB2 mRNA
levels, we also observed increased expression of c-erbB2
mRNA in the absence of DNA amplification in some
tumours. In a small scale study, of 11 primary breast car-
cinomas, of which only three had amplified c-erbB2 DNA,
Van de Vijver et al. (1987) also found that amplification
correlated with RNA overexpression.
Kraus et al. (1987) investigated c-erbB2 expression in a
series of 16 human mammary tumour cell lines. They found
c-erbB2 gene amplification in the four cell lines with the
highest levels of c-erbB2 mRNA. In four other cell lines
where c-erbB2 RNA levels were intermediate, gene
amplification was not detected. In contrast, in the tumour
group we studied we did not find any such association
between the level of RNA overexpression and gene
amplification. We observed elevated c-erbB2 mRNA expres-
sion in some cases with no detectable gene amplification,
which was as high (3-7-fold) as in some examples where the
gene had been amplified. Similar results were obtained by
Varley et al. (1987), studying c-myc overexpression/
amplification in human breast tumours.
Our results suggest that c-erbB2 on mRNA overexpression
in human breast carcinomas could result from changes in
transcriptional regulation or increased mRNA stability, as
well as from DNA amplification. Kraus et al. (1987), in their
studies on c-erbB2 RNA expression in mammary tumour cell
lines, reached a similar conclusion. These authors suggested
that elevation of c-erbB2 transcript levels could precede gene
amplification, conferring an initial selective growth advantage
to the tumour cell, subsequently enhanced and stabilised by
gene amplification.
We have not measured the levels of the c-erbB2 protein
product encoded by the overexpressed mRNA in our study,
due to limited availability of tumour tissue. We cannot
therefore rule out the possibility that post-translational
mechanisms also lead to overexpression of the c-erbB2 pro-
duct. Immunoblotting experiments on a number of mammary
tumour cell line samples with c-erbB2 RNA overexpression
(Kraus et al., 1987) led to the conclusion that, at least in cell
lines, elevated c-erbB2 transcripts are translated into c-erbB2
protein. If, as would seem likely, overexpression of c-erbB2
mRNA in breast tumours is accompanied by elevated protein
levels, then in view of the c-erbB2 transformation
experiments of DiFiore et al. (1987), the detection of in-
creased levels of c-erbB2 RNA expression in human breast
carcinomas may be more clinically relevant than gene
amplification analysis.
Studies of the expression of the c-erbB2 gene product in
primary tumours by immunoctyochemistry (Barnes et al.,
1988; Berger et al., 1988; Venter et al., 1987), also suggest
that breast carcinomas with no apparent c-erbB2 gene
amplification can overexpress the protein. Our observations
on c-erbB2 mRNA overexpression in breast tumours are
consistent with the results of these groups, and lead to the
firm conclusion that there are mechanisms in addition to
c-erbB2 gene amplification leading to overexpression of the
c-erbB2 protein.
ISH analysis confirmed that increased levels of c-erbB2
transcripts, were localised specifically to tumour cells within a
breast tumour section. We have also shown that we could
detect high levels of c-erbB2 RNA by ISH only in those
tumours which had elevated levels of mRNA expression as
determined by RNase mapping. In view of the potential
importance of c-erbB RNA overexpression, the ISH tech-
nique has the advantage of being less subjective than
immunocytochemistry (Barnes et al., 1988) and to some
extent quantitatable by silver grain counting (Parkes et al.,
1988).
In order to evaluate the potential prognostic significance of
c-erbB2 RNAexpression in human breast carcinomas, we
compared the results from our study with known clinical
parameters for our group of patients. In agreement with
other groups' studies of c-erbB protein (Barnes et al., 1988;
Berger et al., 1988), we observed that c-erbB RNA expression
associates with nuclear grade, an existing indicator of prog-
nosis (Stewart & Rubens, 1984). The strong association of
c-erbB2 with poor nuclear grade may imply a potential role
for this oncogene in the neoplastic dedifferentiation of
infiltrating ductal carcinomas. Other workers, however, have
found no evidence of an association between c-erbB2 gene
amplification and clinical parameters of tumours associated
with malignancy (Ali et al., 1988b; Zhou et al., 1987).
Reports on the association between c-erbB2 expression and
steroid receptor levels have also been contradictory. Some
workers have reported that c-erbB2 amplification is cor-
related with oestrogen and progesterone receptor status
(Berger et al., 1988; Zeillinger et al., 1989) while others,
ourselves included, have not found any significant correlation
(Slamon et al., 1987; Gusterson et al., 1988).
Gusterson et al. (1988) reported that they did not detect
any membrane staining for c-erbB2 protein in infiltrating
lobular carcinomas. We also found that c-erbB2 RNA
overexpression was confined to infiltrating ductal carcinomas
and an invasive duct carcinoma with intraductal component.
None of the ILC samples we studied showed any increase in
c-erbB2 RNA levels. However, only 10% of the tumours we
analysed belonged to this group. Investigation of larger
groups may reveal if this result is significant.
The most controversial reports have been those of Slamon
et al. (1987) and Varley et al. (1987) linking c-erbB2 gene
amplification with early disease recurrence in breast cancerC-erbB2 EXPRESSION IN BREAST TUMOURS 45
patients. More recently, Wright et al. (1989) have also sup-
ported the role of the c-erbB2 oncoprotein as a prognostic
indicator. Other studies have been less conclusive (Zhou et
al., 1989; Barnes et al., 1988; Van de Vijver et al., 1988) Our
results suggest a trend towards an association of both
c-erbB2 DNA amplification and RNA overexpression with
decreased disease-free interval, although the correlation was
not statistically significant (P = 0.1-0.05). However, in view
of the frequency of overexpression of c-erbB2 RNA in breast
carcinomas and the trends towards an association with poor
prognosis noted by many authors, including ourselves, we
believe that c-erbB2 does have a role to play in the neoplastic
progression of breast cancer. The exact nature of this func-
tion, and whether it is a causal factor in the disease or an
adaptive response, requires further investigation.
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